WOBURN, Mass. (February 9, 2018) – EarlySense, the market leader in contact-free health monitoring solutions, today announced that the company’s award-winning and clinically-validated Percept fertility tracker, is now eligible as a Flexible Spending Account (FSA) reimbursable expense. Employees with an FSA account can now use their tax-free dollars to purchase Percept, giving more women access to a simple-to-use device that helps them get pregnant more quickly and easily.
Percept is a contact-free device that slips under a mattress, monitors key vital signs such as heart and respiratory rates, and sleep and stress levels, and accurately predicts a woman’s 6-day fertility window. In a recent clinical study, Percept predicted when the user was most fertile with 31% higher accuracy than standard ovulation estimation processes. The information is sent in real-time to a smartphone, empowering women who are trying to get pregnant to conceive faster and plan ahead. Best of all, Percept requires little effort and almost no changes to daily habits.
Percept’s FSA medical reimbursement eligibility comes at a time when an increasing number of employers are offering fertility benefits as a means of attracting and retaining top talent. In a January 2018 study entitled 2017 Maternity, Family and Fertility Survey released by Willis Towers Watson, two-thirds (66%) of employers are expected to offer fertility benefits by 2019, up from 55% in 2017. According to the study, innovative employers view fertility benefits as a means to support diversity initiatives, recruit and retain talent, achieve industry recognition, and align with their corporate strategy or mission.
“Employers are evolving their health care programs to reflect that fertility benefits are becoming more important to many employees…” said Jeff Levin-Scherz, M.D., North American co-leader, health management practice at Willis Towers Watson. “The additional coverage is often a win-win proposition. It allows employers to provide a valued employee benefit while improving their ability to attract and retain top talent and support diversity initiatives.”
“As we continue to develop strategic partnerships with insurers, benefit brokers and consultants, they will be able to provide their customers access to EarlySense technology and products,” said Michael Martocci, Head of Strategic Partnerships and Business Development, North America at EarlySense. “Having Percept approved for FSA reimbursement makes this valuable fertility benefit even more accessible to the consumer.”
EarlySense is backed by the guidance and counsel of the world’s leading physicians, and is the first company to bring clinically-validated and contact-free digital health technology to the women’s fertility tracking market. Percept is listed with the U.S. Food and Drug Administration (FDA) as a device intended to track physiological parameters as an aid to conception. FSA medical reimbursement eligibility now enables even more women to access Percept. Percept retails for $199 and can be purchased directly at www.earlysense.com/percept.